Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.44 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL153338 | 0.85 | HPGD (0.60) | RAB9ANPC1POLBGAAKDM4E | |
| Hydrochloric Acid SCHEMBL17261462 | 0.83 | HPGD (0.59) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL17130336 | 0.83 | RAB9A (0.58) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL27306341 | 0.81 | RAB9A (0.57) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL2225013 | 0.81 | LMNA (0.62) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL533107 | 0.81 | RAB9A (0.53) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL2056124 | 0.81 | GFER (0.72) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL2056125 | 0.81 | TP53 (0.55) | RAB9ANPC1POLBGAAKDM4E | |
| SCHEMBL2817593 | 0.81 | CYP2E1 (0.64) | RAB9ANPC1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL10062532 | 0.81 | RAB9A (0.48) | RAB9ANPC1POLBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| US-8183351-B2 | Avermectin derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-22 | — | — | US | disclosed |
| WO-2012006203-A1 | N-CYCLYL-3 - (CYCLYLCARBONYLAMINOMETHYL) BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| US-7879851-B2 | such as (E)-3-[2-(1-{[2-(5-Bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-1H-indole-6-carbonyl]-amino}-cyclobutyl)-3-methyl-3H-benzoimidazol-5-yl]-acrylic Acid, used for the treatment of hepatitis C virus infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234312-A1 | AVERMECTIN DERIVATIVES | OXTR, C3AR1, CBR3 | RAB9A 596/4885NPC1 2660/4885POLB 4554/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | RAB9A 102/4885NPC1 1411/4885POLB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.